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Introduction {#sec005}
============

Distal radius fracture (DRF) is the most common fracture in adults, and patients aged over 65 years are most at risk of suffering DRF \[[@pone.0232153.ref001]\]. Over the years, various immobilization methods have been described for the treatment of DRFs \[[@pone.0232153.ref002]--[@pone.0232153.ref006]\]. There is, however, a scarcity of studies that compare different cast immobilization methods and there is not enough good-quality evidence to enable the selection of one preferable method over the others \[[@pone.0232153.ref007]\].

The volar-flexion and ulnar deviation cast (VFUDC) immobilization method was first described by Cotton in 1910 \[[@pone.0232153.ref008]\]. The VFUDC is still widely used, since it is thought to maintain the fracture position with ligamentotaxis \[[@pone.0232153.ref009]\]. In another common immobilization technique, functional cast (FC) position, the wrist is stabilized in 0--20 degrees of dorsal angulation, supposedly allowing better ability to function to be maintained and rehabilitation to the wrist and hand.

Radiographs have been used by researchers and physicians to identify and classify DRFs, to select treatment interventions, and to predict the prognosis of patients with DRF. However, the association between radiographic parameters and the prognosis of DRF measured with patient-reported outcome measures (PROMs) is obscured with the dorsally displaced DRFs of patients aged 65 or more \[[@pone.0232153.ref010]--[@pone.0232153.ref016]\]. More recently, various psychological factors, such as depression, catastrophic thinking related to pain, and anxiety, have been shown to be associated with a decrease in the outcomes of DRF treatment \[[@pone.0232153.ref017]--[@pone.0232153.ref019]\].

In this pragmatic \[[@pone.0232153.ref020]--[@pone.0232153.ref022]\], randomized, controlled, multicenter trial, we compare the two commonly used cast immobilization positions, VFUDC position and FC position **(**Figures in [S4 Appendix](#pone.0232153.s005){ref-type="supplementary-material"}), in primarily successfully reduced, dorsally displaced DRFs in patients aged 65 or more. It was hypothesized that VFUDC and FC positions result in similar functional results. Furthermore, we hypothesized that catastrophic thinking related to pain would worsen our primary PROM results, patient-rated wrist evaluation (PRWE) score, regardless of the treatment group at 12 months.

Methods {#sec006}
=======

Trial design {#sec007}
------------

This study is a pragmatic, randomized, controlled multicenter trial that compares two cast immobilization positions, VFUDC position and FC position, of dorsally displaced DRFs in patients aged 65 years and more. The study was conducted at 3 large emergency hospitals in Finland; Tampere University Hospital (Tampere), Central Finland Central Hospital (Jyväskylä), and Satakunta Central Hospital (Pori). The study protocol has been published previously \[[@pone.0232153.ref023]\]. Ethical approval was obtained from each study center. The authors have written the manuscript together and made the joint decision to submit the manuscript for publication. There were a few changes made in the methods and design after the protocol was published. These changes have been identified and described in more detail in appendix ([S2 Appendix](#pone.0232153.s003){ref-type="supplementary-material"}). The trial was registered two months after the first recruitment in the study by the corresponding author after the summer holiday season. A total of three patients were recruited before the registration of the trial at Tampere University Hospital, the main study center. The authors confirm that all ongoing and related trials for this intervention have been registered. The Regional Ethics Committee of Tampere University Hospital approved the protocol of the trial and additional papers, including consent form, patient information sheet, and questionnaires 4/1/2016 (Approval number: ETL R16035). The patients were recruited between July 2016 and May 2017 and followed until May 2019.

Enrolment and randomization {#sec008}
---------------------------

All consecutive patients aged 65 years and more with a successfully reduced, dorsally displaced DRF were eligible for inclusion (criteria are presented in [S1 Appendix](#pone.0232153.s002){ref-type="supplementary-material"}). In this pragmatic study, there were no definitive radiographic criteria for the inclusion, but the national care guidelines followed by the recruiting on-call physicians set the parameters for successfully reduced, dorsally displaced DRF as follows: dorsal angulation \< 15 degrees, radial shortening \< 3 mm, volar angulation \< 20 degrees, intra-articular step \< 1 mm, and radio-ulnar angulation \< 15 degrees \[[@pone.0232153.ref024]\]. All the patients were able to ask for additional information about the trial and informed consent was obtained from all enrolled patients.

After the diagnosis and assessment of informed consent, the patients were randomized to either VFUDC or FC using a random number matrix in block allocation in 1 to 1 ratio fashion. The blocks were stratified by age (65 to 74, and 75 or older), and intra-vs. extra-articular fracture \[[@pone.0232153.ref025],[@pone.0232153.ref026]\]. The treatment allocations from the random number matrix were situated in the emergency room in sealed envelopes.

Procedure {#sec009}
---------

Closed reduction of the fracture was performed under local anesthesia and then the wrist was placed in either functional or VFUD position. Both types of plaster cast were in the form of below-elbow cast. Each site had an example-cast of both immobilization methods as a gold-standard of the final position.

Outcome measures {#sec010}
----------------

The primary outcome measure was the mean difference in Patient-Reported Wrist Evaluation (PRWE) score between study groups at 12 months. The PRWE has 15 questions regarding the subjective ability to function of the wrist and hand rated on an 11-point scale from 0 to 10, giving a total range of 0 to 100 (in which 0 is the best). Secondary outcome measures were the short version of Disabilities of arm, shoulder and hand, Quick-DASH (qDASH, in a scale of 0--100) score, visual analogue scale of pain (VAS, in a scale of 0--100), health-related quality of life (15D, in a scale of 0--1), grip strength, number of complications, number of surgical interventions, number of cast changes, and radiographic parameters. The radiographic parameters were assessed by one of the authors who was blinded to the treatment group at the time of assessment. Catastrophic thinking related to pain was assessed using the pain catastrophizing scale (PCS). The questionnaires with unanswered responses were analyzed by the standards of the user's manual of each patient-reported outcome measure.

Statistical analysis {#sec011}
--------------------

A minimum of 40 patients per group was needed to detect the minimal clinically important difference (MCID) of 11 points on the PRWE scale with standard deviation of 14 points \[[@pone.0232153.ref027]\], a power of 80%, and at a 0.05 confidence level. The drop-out rate was estimated to be 30%.

The primary analysis included all patients who completed the questionnaires at 12-month follow-up. The secondary analysis was performed by including patient loss at follow-up by multiple imputation method. Differences between the two treatment groups in PRWE score, qDASH score, VAS, 15D, grip strength, effect of cast changes on PRWE, number of complications, internal validity of inclusion by post-reduction radiographs, and variance of continuous variables were analyzed using the Student's t-test. Two-way tables with the Fisher exact test were used for dichotomous variables for p-values and logistic regression for confidence intervals. The effect of cast treatment on the number of cast changes was analyzed using the Pearson's chi-square test. The 95% confidence intervals (CI) were calculated for the differences between the selected outcome measures. To assess the linear correlation between two continuous outcome measures, Pearson's correlation coefficients (CC) were calculated. In a subgroup analysis, the effect of various baseline characteristics were analyzed against the PRWE score at three and 12 months in multivariate linear regression. SPSS statistical software, version 25, was used for the analyses in the study. Several secondary analyses were performed in addition to the analyses presented in the protocol. These changes have been identified and described in the appendix file ([S3 Appendix](#pone.0232153.s004){ref-type="supplementary-material"}).

Follow-up {#sec012}
---------

One to 2 weeks after casting, a control appointment was arranged to evaluate the fracture position. If the reduction in fracture alignment was lost, operative treatment was considered by surgeons in accordance with the preferences of the patients in a pragmatic manner. Otherwise patients underwent a five-week cast immobilization period. Guided physiotherapy was introduced if needed ([Table 1](#pone.0232153.t001){ref-type="table"})

10.1371/journal.pone.0232153.t001

###### The baseline characteristics of patients in the and VFUDC and FC groups.

![](pone.0232153.t001){#pone.0232153.t001g}

  Characteristic                                            FC              VFUDC
  --------------------------------------------------------- --------------- ---------------
  Randomized patients                                       50              55
  Age, mean (range)                                         74.6 (65--94)   72.6 (65--89)
  Sex (female/male)                                         44/6            48/7
  Use of ancillary outside or inside of home (yes/no)       10/34           3/47
  Dominant hand (right/left)                                47/2            50/5
  Fracture side (right/left)                                18/32           27/28
  Distance span in week (walk or cycle) in km, mean (SD)    3.5 (3.2)       3.3 (2.9)
  Pain catastrophizing scale, mean (SD)                     9.4 (11.1)      9.3 (12.1)
  Extra-/Intra-articular fractures                          32/18           42/13
  Use of guided physiotherapy after the fracture, yes (%)   21 (48%)        24 (48%)

Patients were analyzed according to the intention-to-treat principle. The follow-up was organized in each center up to three months, and thereafter questionnaires were collected at Tampere University Hospital at 12 months. The assessment table is provided in the protocol of the study \[[@pone.0232153.ref023]\].

Results {#sec013}
=======

Participants {#sec014}
------------

From July 2016 to May 2017, a total of 105 patients from 3 Finnish hospitals were recruited and randomized into the trial and followed up for 12 months until May 2018. The baseline characteristics of the patients are shown in [Table 1](#pone.0232153.t001){ref-type="table"}. The mean age at the time of recruitment was 73.5 years, and 88% of patients were female.

A total of 55 patients were assigned to the FC group and 50 patients to the VFUDC group. Thirteen patients withdrew from the study before the three-month clinical visit and 19 patients did not return the questionnaires mailed to them at 12 months after recruitment. Therefore, 86 patients were included in the primary, intention-to-treat analysis at 12 months ([Fig 1](#pone.0232153.g001){ref-type="fig"}).

![The flow diagram of the study (CONSORT).\
^a^PRWE = patient-rated wrist evaluation.](pone.0232153.g001){#pone.0232153.g001}

Outcomes at 3 and 12 months {#sec015}
---------------------------

### PROMs and health-related quality of life {#sec016}

The primary outcome measure, PRWE score with intention-to-treat analysis, was measured at 12 months. Results from the primary and secondary outcome measures are summarized in [Table 2](#pone.0232153.t002){ref-type="table"}. At 12 months, the mean (CI for difference in means) PRWE score was 15.5 and 20.4 (-13.1--3.4, p = .24), the qDASH score was 17.2 and 20 (-10.4--5.0, p = .47), and the VAS was 12.6 and 15.6 (-10.9--4.9, p = .51) for the FC and VFUDC groups, respectively. The mean (CI) grip strength of the fractured side in proportion to the controlled side measured at 3 months was 51% for the FC group and 45% for the VFUDC group (-0.26--0.14, p = .17). The changes during follow-up and differences between study groups in 15D were nonexistent in the study ([Table 2](#pone.0232153.t002){ref-type="table"}). The correlation between the grip strength of the uninjured limb at 3 months did not correlate with the PRWE at 3 months (CC: 0.01, p = .92). The correlation between 15D and PRWE was present at 3 months (CC: -0.41, p \< .001) and at 12 months (CC: -0.41, p \< .001).

10.1371/journal.pone.0232153.t002

###### Primary, intention-to-treat analysis of outcome measures for the VFUDC and FC treatment groups at baseline, three, and twelve months after dorsally displaced DRF.

![](pone.0232153.t002){#pone.0232153.t002g}

  Evaluation   VFUDC group   N    FC group   N    SD total   Difference between groups (95% confidence interval)   P-value
  ------------ ------------- ---- ---------- ---- ---------- ----------------------------------------------------- ---------
  PRWE                                                                                                             
   3 months    36.0          47   30.6       44   22.4       -5.4 (-14.7--3.9)                                     .25
   12 months   20.4          47   15.5       39   19.2       -4.9 (-13.1--3.4)                                     .24
  Quick-DASH                                                                                                       
   3 months    34.7          44   31.3       38   22.9       -3.4 (-13.5--6.7)                                     .51
   12 months   20.0          46   17.2       38   17.5       -2.8 (-10.4--4.9)                                     .47
  15D                                                                                                              
   3 months    0.89          46   0.87       43   0.12       -0.02 (-0.07--0.03)                                   .40
   12 months   0.89          47   0.87       39   0.11       -0.01 (-0.06--0.04)                                   .61
  VAS (mm)                                                                                                         
   3 months    24.3          50   21.0       44   19.6       -3.3 (-11.4--4.7)                                     .41
   12 months   15.6          46   12.6       38   18.1       -3.0 (-10.9--4.9)                                     .51
  PCS                                                                                                              
   Baseline    9.3           52   9.4        42   11.6       0.1 (-4.6--4.8)                                       .97
   3 months    10.0          45   8.8        40   10.9       1.2 (-3.6--5.9)                                       .71
   12 months   12.2          38   8.6        35   13.0       -3.6 (-9.6--2.5)                                      .38

Radiographs {#sec017}
-----------

The measured indicators from radiographs showed a small difference between the groups ([Table 3](#pone.0232153.t003){ref-type="table"}). The radiographic confirmation of the differences between the two immobilization methods was performed using measurements of ulnar deviation of the third metacarpal compared with the radial axis and angulation of the wrist comparing second metacarpal flexion/extension to radial axis, having differences in means (CI) -4.0 (-6.0 - -2.0, p \< .001) and 12.4 (8.2--16.2, p \< .001) degrees of difference between the groups, respectively.

10.1371/journal.pone.0232153.t003

###### Mean values of radiographic outcome measures and mean differences between VFUDC and FC position groups.

![](pone.0232153.t003){#pone.0232153.t003g}

  Evaluation                                        VFUDC group   N    FC group      N    Difference between groups (95% confidence interval)   P-value
  ------------------------------------------------- ------------- ---- ------------- ---- ----------------------------------------------------- ---------
  Ulnar variance                                                                                                                                
   Before CR[\*](#t003fn001){ref-type="table-fn"}   3.7           55   3.4           50   -0.3 (-1.5--0.6)                                      .59
   After CR                                         1.1           55   1.5           50   0.4 (-0.4--1.2)                                       .69
   At 3 months                                      3.2           50   4.4           43   1.2 (0.1--2.4)                                        .04
  Inclination                                                                                                                                   
   Before CR                                        15.5          55   17.0          50   1.5 (-0.2--3.2)                                       .09
   After CR                                         18.8          55   18.8          50   -0.02 (-1.4--1.4)                                     .98
   At 3 months                                      17.2          50   16.3          43   -0.9 (-2.6--0.8)                                      .30
  Dorsal angulation                                                                                                                             
   Before CR                                        27.5          55   23.7          50   -3.8 (-8.1 ---0.5)                                    .09
   After CR                                         7.4           55   8.8           50   1.4 (-1.6--4.4)                                       .37
   At 3 months                                      12.8          50   11.9          43   -0.9 (-5.2--3.4)                                      .67
  Extra- / Intra-articular (% extra)                42/13 (76%)        32/18 (64%)                                                              .20
  3-MCP-Radius ulnar deviation                                                                                                                  
   After CR                                         8.6                4.5                -4.0 (-6.0 ---2.01)                                   .00
  Wrist flexion (+) or extension (-)                                                                                                            
   After CR                                         15.5               3.1                -12.4 (-16.3 ---8.4)                                  .00

\*CR = closed reduction.

PCS {#sec018}
---

The PCS score at the time of recruitment did not correlate with PRWE score, qDASH score, or VAS at 12 months, although the PCS score at 3 months did correlate moderately with the PRWE score (CC: 0.19, p = .1), and slightly with the qDASH score (CC:0.14, p. = .24), and VAS (CC: .17, p = .17) at 12 months. An increase in the patient-specific PCS value between baseline and 12 months did correlate moderately with a worsening (increase in value) of the PRWE score at 12 months (CC: 0.24, p = .05).

Complications {#sec019}
-------------

Complications are summarized in [Table 4](#pone.0232153.t004){ref-type="table"}. Operative treatment due to loss of reduction of fracture was performed for four patients in the FC group and for seven patients in the VFUDC group. Pain and stiffness were reported at the outpatient clinic at 3 months, and both pain and stiffness were found to be less in the FC group ([Table 4](#pone.0232153.t004){ref-type="table"}). The number of cast changes was reported by the patients. During the five-week cast immobilization period, 14 cast changes occurred in the FC group compared with 25 cast changes in the VFUDC group (p = .55). In addition, the mean difference in PRWE score at 12 months was -8.5 points (CI: -18.0--1.1, p = .08) lower if no cast changes occurred compared with one or more cast changes. In the VFUDC group, two patients had electroneuromyography (ENMG), compared to none in the FC group, performed for the injured wrist and hand during the follow-up period due to complaints of numbness, but none needed surgery for the condition.

10.1371/journal.pone.0232153.t004

###### Reported complications, operative treatment, and cast changes among study groups.

![](pone.0232153.t004){#pone.0232153.t004g}

  Evaluation                                 VFUDC         FC          Odds ratio[\*](#t004fn001){ref-type="table-fn"} (95% CI)   P-value
  ------------------------------------------ ------------- ----------- ---------------------------------------------------------- --------------------------------------------
  Outpatient visit at 3 months, yes/no (%)                                                                                        
   Reported pain                             14/39 (26%)   4/42 (9%)   (0.08--0.90)                                               .04
   Reported stiffness                        5/48 (9%)     0/46 (0%)   (0.00 - )                                                  .06
  Questionnaires at 12 months, yes (%)                                                                                            
   Operative treatment                       7/55 (13%)    4/50 (8%)   (0.16--2.13)                                               .45
  Questionnaires at 12 months                                                                                                     
   Cast changes                                                                                                                   
    0                                        35            34                                                                     
    1                                        7             6                                                                      
    2                                        6             4                                                                      
    3                                        2             0                                                                      .55[\*\*](#t004fn002){ref-type="table-fn"}

\*The logistic regression was performed to calculate confidence intervals for odds ratio.

\*\*The Chi square test was utilized to calculate the p-value.

Secondary analysis and linear regression {#sec020}
----------------------------------------

After adjustment by patients lost to follow-up using the multiple imputation method, between group differences in means (CI) at 12 months for PRWE score was -3.9 (-12.0--4.2, p = .34), for qDASH score -2.1 (-9.4--5.3, p = .58), and for VAS at 12 months -2.5 points (-10.0--4.9, p = .50) in favor of the FC group.

In linear regression, variance in any of the baseline characteristics computed (age, sex, handedness, PCS, weekly distance span, ancillary use outside of home), was not found to explain variance, i.e., predicting value in PRWE score at 12 months. The R2 of the linear regression was 11.8% and the estimates of coefficients were for age 0.20 (CI: -0.67--1.07) and for PCS at baseline 0.16 (CI: -0.21--0.52).

Discussion {#sec021}
==========

In this randomized, multicenter, pragmatic trial, we compared FC and VFUDC positions in patients aged 65 years or more with dorsally displaced DRF. At 12 months, we found minor differences favoring the FC position in primary and secondary outcomes including complications.

PRWE score at 12 months showed between group difference of 4.9 points when the published MCID of the PRWE is 11 points. The 95% CI of difference in means includes greater than MCID size of advantage of FC and zero points of difference, hence the possibility of FC being distinctly better, or equality of the interventions, cannot be excluded. Further, many of the secondary outcomes showed a tendency to favor the FC position but included the similarity of difference of means in 95% CI. The rate of surgery due to loss of reduction, number of cast changes, and stiffness and pain in the wrist or hand reported at outpatient clinic at 3 months all had minor differences favoring the FC position.

In the present study, there were 14 cast changes in the FC group and 25 in the VFUDC group. Studies investigating cast immobilization methods have not routinely reported on cast changes, but studies have reported various rates of cast changes \[[@pone.0232153.ref026],[@pone.0232153.ref028]--[@pone.0232153.ref030]\]. In our study, it was found that those patients who had one or more cast changes had worse PRWE outcomes at 12 months compared with patients who had no cast changes.

The secondary outcomes of grip strength, qDASH score and PRWE score at 3 months and qDASH score and VAS of pain at 12 months showed a small but constant difference between the studied groups. Grip strength in proportion to the controlled side at 3 months was 51% in the FC group and 45% in the VFUDC group, which is in line with two other RCTs on elderly DRF patients that reported grip strength in proportion to controlled side at 3 months to be 58% and 47% in non-operative groups \[[@pone.0232153.ref012],[@pone.0232153.ref031]\].

In 1991, Gupta published the results of three different immobilization positions with 204 patients: volar-flexion, neutral, and dorsal-flexion, and found in favor of the dorsal-flexion group \[[@pone.0232153.ref006]\]. Van der Linden and Ericson studied 250 patients randomly assigned to five different immobilization positions and found that position had no importance regarding the final results \[[@pone.0232153.ref032]\]. Rajan et al. found better grip strength and less pain, disability, and limitation of movements in a dorsal-flexion group compared with a volar-flexion group \[[@pone.0232153.ref033]\]. Grle et al. studied 100 patients and found that dorsal-flexion was of minor benefit compared with volar-flexion at 2-month follow-up \[[@pone.0232153.ref034]\]. The results of our study, in line with the findings of the above studies, suggest that volar-flexion is not a superior cast position after dorsally displaced DRF.

Although some studies have reported the prognostic and explanatory value of various psychological factors on the PROM outcomes of DRF \[[@pone.0232153.ref017]--[@pone.0232153.ref019]\], this study did not find a prognostic value of PCS at baseline for PRWE measured at 12 months, as was hypothesized, though a modest correlation value of PCS at 3 months with PRWE at 12 months was present. However, the rise in the patient-specific value of PCS between baseline and 12 months did show moderate correlation in PRWE at 12 months, which suggests that pain avoidance and catastrophic thinking related to pain is dynamic in nature and evolves in association with new experiences.

The assessed mean values of the radiographical indicators of inclusion validity and procedural validity after the closed reduction indicate that the recruiting on call physicians enrolled patients who were well aligned to the Finnish Current Care Guidelines \[[@pone.0232153.ref024]\] used at the time of enrolment to determine between non-operative and operative treatment. In this respect, there were no considerable differences between the findings of the three participating centers in the study. Furthermore, the internal validity of the two cast positions were assessed by two radiographical indicators which showed mean differences in radial angulations by the two studied interventions, as expected.

The rates of reported complications were low in both groups. We found, however, that the VFUDC group reported more stiffness and pain at outpatient clinic at 3 months. When taken together with the biomechanical study \[[@pone.0232153.ref035]\], this finding might suggest an elevated risk of median nerve compression in the VFUDC position when compared with the FC position. Moreover, two patients in the VFUDC group and none in FC group underwent ENMG on their injured forearm during follow-up.

This study has several limitations that should be considered. The follow-up of patients aged 65 years or more with dorsally displaced DRF at the time of closed reduction was limited to 12 months. The cast immobilization methods studied were limited to two widely used cast positions, although several other immobilization methods have been presented in the literature \[[@pone.0232153.ref002]--[@pone.0232153.ref006]\]. The sample size used does not permit convincing conclusions for infrequent outcomes, such as the difference in rate of complications, nor for the small differences between groups in continuous variables between the two studied interventions. Moreover, the SD of our primary outcome, PRWE score at 12 months, was larger than anticipated and utilized in a priori power calculation.

Conclusions {#sec022}
===========

In summary, the authors suggest that FC immobilization might lead to slightly more beneficial subjective functional outcomes with fewer complications when compared with VFUDC immobilization in the treatment of this common fracture but the similarity of the outcomes in 95% confidence interval cannot be excluded. In the clinical context of DRF treatment, the arm has to be immobilized to some cast position and, taken together with the results of our and previous studies, FC is more likely to result in superior outcomes than VFUDC.
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4.  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: well done study statistical methodology sound

addresses a contemporary question now that so many of these fractures are treated operatively

This reviewer has little critique with your overall methodology nor conclusions

Reviewer \#2: This investigation is well and completely reported and discussed. The English language is poor, even unclear, in parts (e.g., section 'PCS' in the appendix) and needs to be revised by a native speaker or other competent person. I have only minor comments and suggestions:

1\. Please state the randomisation block size. According to the stated stratification factors, there seem to have been 2x3x2 = 12 strata, which for planned 57 patients per group would seem to lead to very numbers in each stratum.

2\. The statistics software used for data analysis should be stated.

3\. Detail of the multiple imputation procedure used should be given in the appendix.

4\. Please state which outcome variables were collected at baseline, and the time-point of the outcome. In Table 2, only PCS is given at baseline. Further, which 'difference' is meant in the sentence beginning 'The primary outcome measure was the difference...', p.5? I understand that the PRWE was not measured at baseline, so presumably you mean the difference between the treatment groups? Generally, an 'outcome' should be defined on the individual patient.

5\. I assumed that all localised outcome measures refer to the injured wrist, but on p.8 we are informed about the correlation with grip strength of the uninjured limb -- please clarify.

6\. When were the radiograph examinations and assessments performed, and were the assessors blinded to treatment group?

7\. I suggest displaying the distribution of primary (and possibly important secondary) outcome values graphically, for instance using box-plots or scatter plots comparing the treatment groups.

8\. Were subgroup analyses per site performed and if so, were any differences found? In such a surgery study, where physician-specific effects may be expected, it would be important to look for site subgroup differences in the primary treatment comparison.

9\. On p.13 (discussion) a cast change rate per patient of 260% is referred to -- does this mean multiple changes in some patients?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Jeremy Franklin

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Rebuttal letter

We would like to take this opportunity to thank the Reviewers for their constructive criticism of our manuscript. We have strived to revise the manuscript in accordance with the valuable criticism received from the Reviewers. We feel that the quality of our manuscript has improved as a result.

The comments of the Reviewers are followed by our answers and a description of the corrections/changes that we have made to the manuscript (marked in italics).

Reviewers\' comments:

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

We have now verified the policies of our Regional Ethical Committee on data sharing. In order to ensure the anonymization of the dat. Hence, the exact day and month of the recruitment has been removed and study centers are only referred to as numbers one, two, and three. Due to the common nature of distal radius fracture, we feel these changes enable the required anonymization of the data. The data will be submitted in the supplementary file alongside the manuscript.

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

5\. Review Comments to the Author

Reviewer \#1: well done study statistical methodology sound addresses a contemporary question now that so many of these fractures are treated operatively. This reviewer has little critique with your overall methodology nor conclusions.

The authors thank the reviewer for the positive comments.

Reviewer \#2: This investigation is well and completely reported and discussed. The English language is poor, even unclear, in parts (e.g., section 'PCS' in the appendix) and needs to be revised by a native speaker or other competent person. I have only minor comments and suggestions:

The authors thank the reviewer for the positive comments. The material in the supplementary files has now been revised by a native speaker of English.

1\. Please state the randomisation block size. According to the stated stratification factors, there seem to have been 2x3x2 = 12 strata, which for planned 57 patients per group would seem to lead to very numbers in each stratum.

In the randomization process, we had two stratification variables, age and extra- or intra-articular fracture line, with two blocks in each variable. Thus, there were 4 stratification factors (lines 116-7).

2\. The statistics software used for data analysis should be stated.

The statistical software used for the data analysis was SPSS v. 25 (lines 147-8).

3\. Detail of the multiple imputation procedure used should be given in the appendix.

The variables used for the multiple imputation were age, sex, cast position (treatment allocation), the PRWE at 3 and 12 months, the PCS at 3 and 12 months, the VAS for pain at 3 and 12 months, and the Quick-DASH at 3 and 12 months. This has now been explained in more detail in appendix S4.

4\. Please state which outcome variables were collected at baseline, and the time-point of the outcome. In Table 2, only PCS is given at baseline. Further, which 'difference' is meant in the sentence beginning 'The primary outcome measure was the difference...', p.5? I understand that the PRWE was not measured at baseline, so presumably you mean the difference between the treatment groups? Generally, an 'outcome' should be defined on the individual patient.

The mean difference between study groups at 12 months was the primary outcome. This has now been stated more clearly (lines 126-7).

5\. I assumed that all localised outcome measures refer to the injured wrist, but on p.8 we are informed about the correlation with grip strength of the uninjured limb -- please clarify.

The reviewer is indeed correct that we have reported the correlation with the grip strength of the uninjured limb to the PRWE score in order to find an association, if any, between the physical strength of the upper arms and the primary outcome.

6\. When were the radiograph examinations and assessments performed, and were the assessors blinded to treatment group?

The radiograph examinations were performed before and after the closed reduction, 1, 2, and 5 weeks after fracture. The radiographic assessments were performed by authors who were blinded to the treatment allocation at the time of assessments (lines 133-4).

7\. I suggest displaying the distribution of primary (and possibly important secondary) outcome values graphically, for instance using box-plots or scatter plots comparing the treatment groups.

The authors fully agree with the usefulness of the graphical reporting of the main results. We have now added a box-plot graph that contains the results of the PRWE, the Quick-DASH, and VAS for pain in appendix S4.

8\. Were subgroup analyses per site performed and if so, were any differences found? In such a surgery study, where physician-specific effects may be expected, it would be important to look for site subgroup differences in the primary treatment comparison.

In each study center, recruitment to the study and the closed reduction of the fracture was performed by various on-call physicians in the emergency departments. Therefore, each physician only recruited and treated a few patients in the study. The subgroup analysis of radiograph parameters for the internal validation of the allocated treatment showed no difference between study centers.

9\. On p.13 (discussion) a cast change rate per patient of 260% is referred to -- does this mean multiple changes in some patients?

This rate of cast changes has been referred to in a paper published by Anzarut et a.l (ref 26 in the manuscript) who reported in Table 1 of the article the mean of 2.6 and the median of 2 cast changes in the study population. However, we are not confident in this reported number and we have therefore changed the sentence: "Studies investigating cast immobilization methods have not routinely reported on cast changes, but studies have reported various rates of cast changes" (lines 270-1).
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Dear Dr. Raittio,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jesse Bernard Jupiter, MD

Guest Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: no further comments. The authors have fully complied with the suggests made by the reviewers and improved the overall clarity

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Jeremy Franklin
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Acceptance letter

Jupiter

Jesse Bernard

Guest Editor

© 2020 Jesse Bernard Jupiter

2020

Jesse Bernard Jupiter

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

27 Apr 2020

PONE-D-19-23143R1

Two casting methods compared in patients with Colles\' fracture: A pragmatic, randomized controlled trial

Dear Dr. Raittio:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. PLOS Manuscript Reassignment

Staff Editor

PLOS ONE
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